$1.03
-6.36% (Daily)
Market Cap
$2.76M
Revenue
$601.00K
Rank by MCap
#1692
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Maurice Zauderer Ph.D.
Headquarters
Rochester, NY
Employees
23
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 clinical for the treatment of Alzheimer's disease and has completed phase 2 study for the treatment of Huntington's disease; Pe...
Loading chart…